Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Quantitative volumetric imaging of normal, neoplastic and hyperplastic mouse prostate using ultrasound.

Singh S, Pan C, Wood R, Yeh CR, Yeh S, Sha K, Krolewski JJ, Nastiuk KL.

BMC Urol. 2015 Sep 21;15:97. doi: 10.1186/s12894-015-0091-9.

2.

Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism.

Lin X, Jia J, Du T, Li W, Wang X, Wei J, Lin X, Zeng H, Yao L, Chen X, Zhuang J, Weng J, Liu Y, Lin J, Wu Q, Wang W, Yao K, Xu K, Xiao D.

PLoS One. 2015 Mar 23;10(3):e0118417. doi: 10.1371/journal.pone.0118417. eCollection 2015.

3.

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.

Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME.

PLoS One. 2015 Feb 18;10(2):e0117758. doi: 10.1371/journal.pone.0117758. eCollection 2015.

4.

Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.

Ju HL, Calvisi DF, Moon H, Baek S, Ribback S, Dombrowski F, Cho KJ, Chung SI, Han KH, Ro SW.

Sci Rep. 2015 Jan 27;5:8053. doi: 10.1038/srep08053.

5.

Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.

Nandana S, Chung LW.

Am J Clin Exp Urol. 2014 Jul 12;2(2):92-101. eCollection 2014. Review.

6.

Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Adisetiyo H, Liang M, Liao CP, Jeong JH, Cohen MB, Roy-Burman P, Frenkel B.

J Cell Physiol. 2014 Sep;229(9):1170-6. doi: 10.1002/jcp.24546.

7.

Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy.

Zhong R, Pytynia M, Pelizzari C, Spiotto M.

Cancer Res. 2014 Apr 1;74(7):2073-81. doi: 10.1158/0008-5472.CAN-13-2993. Epub 2014 Feb 13.

8.

CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features.

Geary LA, Nash KA, Adisetiyo H, Liang M, Liao CP, Jeong JH, Zandi E, Roy-Burman P.

Mol Cancer Res. 2014 Apr;12(4):607-21. doi: 10.1158/1541-7786.MCR-13-0469. Epub 2014 Jan 24.

9.

Mouse models of prostate cancer: picking the best model for the question.

Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ.

Cancer Metastasis Rev. 2014 Sep;33(2-3):377-97. doi: 10.1007/s10555-013-9487-8. Review.

10.

Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis.

Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, Gill PS.

Clin Cancer Res. 2013 Dec 15;19(24):6802-11. doi: 10.1158/1078-0432.CCR-13-1106. Epub 2013 Sep 18.

11.

Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Pham LK, Liang M, Adisetiyo HA, Liao CP, Cohen MB, Tahara SM, Frenkel B, Kasahara N, Roy-Burman P.

Endocr Relat Cancer. 2013 Nov 4;20(6):861-74. doi: 10.1530/ERC-13-0100. Print 2013 Dec.

12.

Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma.

Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P.

PLoS One. 2013 Jul 31;8(7):e69484. doi: 10.1371/journal.pone.0069484. Print 2013.

13.

Detection and organ-specific ablation of neuroendocrine cells by synaptophysin locus-based BAC cassette in transgenic mice.

Cheng CY, Zhou Z, Nikitin AY.

PLoS One. 2013 Apr 22;8(4):e60905. doi: 10.1371/journal.pone.0060905. Print 2013.

14.

Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.

Kocher B, Piwnica-Worms D.

Cancer Discov. 2013 Jun;3(6):616-29. doi: 10.1158/2159-8290.CD-12-0503. Epub 2013 Apr 12. Review.

15.

Non-invasive molecular imaging for preclinical cancer therapeutic development.

O'Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH.

Br J Pharmacol. 2013 Jun;169(4):719-35. doi: 10.1111/bph.12155. Review.

16.

Genetically engineered mouse models of prostate cancer.

Parisotto M, Metzger D.

Mol Oncol. 2013 Apr;7(2):190-205. doi: 10.1016/j.molonc.2013.02.005. Epub 2013 Feb 14. Review.

17.

JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.

Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL, Flavell RA, Wu H, Davis RJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12046-51. doi: 10.1073/pnas.1209660109. Epub 2012 Jul 2.

18.

In vivo optical imaging and dynamic contrast methods for biomedical research.

Hillman EM, Amoozegar CB, Wang T, McCaslin AF, Bouchard MB, Mansfield J, Levenson RM.

Philos Trans A Math Phys Eng Sci. 2011 Nov 28;369(1955):4620-43. doi: 10.1098/rsta.2011.0264. Review.

19.

Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.

Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD.

Am J Pathol. 2011 Jul;179(1):502-12. doi: 10.1016/j.ajpath.2011.03.014. Epub 2011 May 7.

20.

TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.

Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA, Jung JU.

PLoS One. 2011 Jan 18;6(1):e16205. doi: 10.1371/journal.pone.0016205.

Supplemental Content

Support Center